Thus, we tested the hypothesis that the concerted molecular interplay between testosterone-associated HSD17B2, HSD17B3, SHBG, and SRD5A1 determine therapy response and susceptibility to disease relapse in patients with PCa. The gene discussed is SHBG; the disease is posterior cortical atrophy.